Pancreatic Cancer Research

ResearcherKyorin UniversityActive in the last 2 years

Masato Ozaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5666-1970; OpenAlex author ID A5021509769. Sources: OpenAlex.

Their work

Papers
96 (first author 10, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
212
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 4 papers · 2019: 4 papers · 2020: 8 papers · 2021: 10 papers · 2022: 10 papers · 2023: 14 papers · 2024: 7 papers · 2025: 16 papers · 2026: 17 papers

Papers 50 of 96

  1. Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. Co-author DOI 10.1002/bcp.70611↗
  2. Endoscopic Retrograde Cholangiopancreatography-guided Biliary Drainage with Duckbill-type Anti-reflux Metal Stent versus Endoscopic Ultrasound-guided Hepaticog… Co-author DOI 10.1002/deo2.70154↗
  3. Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer. Co-author DOI 10.1002/ijc.70637↗
  4. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. First author DOI 10.1002/jhbp.70058↗
  5. Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-026-03201-0↗
  6. Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-… Co-author DOI 10.1007/s10637-026-01632-0↗
  7. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. Co-author DOI 10.1016/j.esmogo.2026.100365↗
  8. Circulating SDF4 as a potential diagnostic marker for early-stage pancreatic cancer Co-author DOI 10.1038/s41598-026-63925-x↗
  9. Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinoteca… First author DOI 10.1093/jjco/hyaf194↗
  10. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… First author DOI 10.1093/jjco/hyag055↗
  11. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000002600↗
  12. Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study. Co-author DOI 10.1111/cas.70344↗
  13. Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer. Co-author DOI 10.1159/000550483↗
  14. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  15. Patient-derived orthotopic xenograft models recapitulate the peritoneal dissemination of pancreatic cancer and delineate its transcriptional and regulatory pro… Co-author DOI 10.1186/s13046-026-03668-9↗
  16. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  17. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  18. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  19. Outcomes of multi-hole self-expandable metal stents versus fully covered self-expandable metal stents for malignant distal biliary obstruction in unresectable … Co-author DOI 10.1002/deo2.70014↗
  20. Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer. First author DOI 10.1007/s10147-025-02796-0↗
  21. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  22. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Co-author DOI 10.1016/j.ejso.2025.109635↗
  23. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  24. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.06.013↗
  25. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  26. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  27. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design. Co-author DOI 10.1080/14796694.2025.2469467↗
  28. Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Co-author DOI 10.1093/bjsopen/zraf026↗
  29. [Multidisciplinary treatment for borderline resectable pancreatic cancer]. First author DOI 10.11405/nisshoshi.122.810↗
  30. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… First author DOI 10.1200/jco.24.00936↗
  31. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-17407-5↗
  32. Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. Co-author DOI 10.2169/internalmedicine.3577-24↗
  33. Factors Affecting Delayed Recovery from Neutropenia in Patients with Pancreatic Cancer Receiving Gemcitabine plus Nab-Paclitaxel. Co-author DOI 10.7150/jca.107359↗
  34. Outcomes of 6-mm diameter fully covered self-expandable metal stents for preoperative biliary drainage in pancreatic cancer. Co-author DOI 10.1002/deo2.360↗
  35. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… First author DOI 10.1016/j.pan.2024.07.006↗
  36. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  37. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  38. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Co-author DOI 10.1093/bjs/znad417↗
  39. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyae028↗
  40. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline re… Co-author DOI 10.1093/jjco/hyae084↗
  41. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Co-author DOI 10.1002/deo2.205↗
  42. Outcomes of pancreatic cancer with liver oligometastasis. Co-author DOI 10.1002/jhbp.1184↗
  43. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Co-author DOI 10.1007/s00464-022-09836-0↗
  44. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  45. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  46. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Co-author DOI 10.1016/j.hpb.2022.09.012↗
  47. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Co-author DOI 10.1016/j.pan.2023.02.002↗
  48. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  49. Outcomes of lung oligometastasis in pancreatic cancer. Co-author DOI 10.1093/jjco/hyad111↗
  50. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗

Closest collaborators

The 25 strongest of 212 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naoki Sasahira · 64 shared papers, 2018–2026 · strength 11.41
  2. Takashi Sasaki · 48 shared papers, 2018–2026 · strength 8.11
  3. Takafumi Mie · 40 shared papers, 2020–2026 · strength 6.91
  4. Tsuyoshi Takeda · 38 shared papers, 2020–2026 · strength 6.47
  5. Takaaki Furukawa · 34 shared papers, 2020–2026 · strength 5.79
  6. Takeshi Okamoto · 26 shared papers, 2021–2026 · strength 4.88
  7. Akiyoshi Kasuga · 27 shared papers, 2020–2025 · strength 3.97
  8. Makoto Ueno · 24 shared papers, 2014–2026 · strength 3.57
  9. Masato Matsuyama · 27 shared papers, 2014–2023 · strength 3.43
  10. Yu Takahashi · 16 shared papers, 2020–2026 · strength 2.69
  11. Atsushi Oba · 14 shared papers, 2022–2026 · strength 2.57
  12. Junji Furuse · 16 shared papers, 2018–2026 · strength 2.43
  13. Masafumi Ikeda · 16 shared papers, 2018–2026 · strength 2.35
  14. Yosuke Inoue · 13 shared papers, 2020–2026 · strength 2.35
  15. Satoshi Kobayashi · 17 shared papers, 2018–2026 · strength 2.20
  16. Yuto Yamada · 16 shared papers, 2020–2023 · strength 2.14
  17. Yoshihiro Ono · 12 shared papers, 2021–2026 · strength 2.10
  18. Hiromichi Ito · 11 shared papers, 2022–2026 · strength 2.02
  19. Naohiro Okano · 14 shared papers, 2018–2026 · strength 1.89
  20. Hiroshi Ishii · 18 shared papers, 2012–2026 · strength 1.88
  21. Nobumasa Mizuno · 15 shared papers, 2018–2026 · strength 1.87
  22. Aya Maekawa · 8 shared papers, 2024–2026 · strength 1.65
  23. Takuji Okusaka · 12 shared papers, 2014–2026 · strength 1.60
  24. Chigusa Morizane · 8 shared papers, 2022–2026 · strength 1.55
  25. Akiko Todaka · 12 shared papers, 2018–2025 · strength 1.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.